retatrutide phase 2 nejm 2023 obesity trial results 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending The trial that put “24%”

Cancer-associated fibroblast-secreted exosomal miR-454-3p inhibits lipid metabolism and ferroptosis in breast cancer by targeting ACSL4

Stepping into this void have been the compounding pharmacies that can produce versions of these drugswhich they are permitted to do for any drug on the FDAs shortages list if they meet certain federal law requirements

For moderate overdoses (two to three times the intended dose), symptoms are usually self-limiting

When injecting something into your body, you want to make sure it is both pure and sterile

A single high-sodium meal can cause 2 to 4 pounds of water retention that takes 48 to 72 hours to clear